The second trial to report was the double-blind placebo-controlled randomized phase III PENELOPE-B trial, which enrolled women with high-risk hormone receptor-positive HER2- primary breast cancer with residual invasive disease after taxane-containing neoadjuvant chemotherapy (57). Here, ERBB2 is linked to breast cancer.